Rare Disease Patient Recruitment
for market research and clinical studies
Verified patients, caregivers, and clinicians — recruited with HIPAA- and GDPR-aligned protocols.
What to expect at a glance
Typical turnaround for a feasibility
assessment.
Common recruitment window after kickoff (varies by incidence and criteria).
HIPAA and GDPR safeguards protect participant data.
Rare disease patient recruitment plays a key role in successful market research and clinical studies. MedPanel connects researchers with verified patients, caregivers, and healthcare professionals across the globe, making recruitment faster and more reliable.
Why rare disease recruitment is different
In the United States, a condition is considered rare when it affects fewer than 200,000 people. Populations stay small, geographically dispersed, and frequently diagnosed late compared with common diseases.
By contrast, traditional outreach and broad consumer panels often miss incidence entirely. At MedPanel, rare disease recruitment is treated as a core competency rather than an add-on.
Physician partners who see rare disease patients daily anchor sourcing efforts. Advocacy collaborations and a growing community of verified respondents extend reach while keeping consent and privacy intact.
See how feasibility, fieldwork, and reporting connect across markets
Conditions we recruit for
Recent projects have included participants living with the following diagnoses, among many others:
Not seeing your indication listed?
Request a feasibility review — most assessments return within 3–5 business days when inclusion and exclusion rules are clear. Niche populations can often be evaluated quickly once screening logic is documented.
Planning a wider program?
The case studies page illustrates comparable engagements across therapeutic areas.
How the recruitment process works
To keep projects efficient, rare disease recruitment follows a structured path from feasibility through delivery. Related advisory and market research programs can reuse those same checkpoints end to end.
1
Feasibility assessment
Target condition, sample criteria, and study timelines are reviewed; a feasibility estimate typically arrives within 3–5 business days at no cost.
2
Participant identification
Candidates are sourced through physician partnerships, patient advocacy channels, and verified respondent communities.
3
Diagnosis verification
Every participant is confirmed via physician attestation, medical record review, or patient-portal validation — never self-report alone.
4
Compliant data collection
Outreach, screening, and data handling follow HIPAA and GDPR requirements to protect confidentiality.
5
Delivery and reporting
Qualified respondents arrive on schedule with quality checks and project management through closeout.
Frequently asked questions
How long does rare disease patient recruitment take?
Most engagements finish within about two to four weeks after kickoff. Feasibility memos typically return within 3–5 business days during the opening phase.
Ultra-rare indications with extremely small pools may need extra calendar time — expectations are set upfront before fieldwork begins.
How do you verify that participants have the condition?
Three verification paths are used, depending on the protocol: physician confirmation, documentation review, or patient-portal checks. Self-reported diagnosis alone is never treated as sufficient evidence of eligibility.
Can you recruit both patients and caregivers?
Certainly — especially for pediatric or dependent populations, caregiver voices matter as much as patient narratives. Screening can target primary caregivers, co-caregivers, or other defined support roles when the brief requires it.
What types of research do you support?
Qualitative designs (depth interviews, focus groups), quantitative surveys, hybrids, and bespoke methodologies are all in scope. Both one-off studies and longitudinal panels can be structured around the same verification standards.
Do you work internationally?
Global recruitment is available, with GDPR-aligned processes for European participants and localized expertise in priority markets. When needed, outreach tactics adapt to regional regulatory and cultural expectations without weakening compliance.
Compliance and data standards
Controls are embedded at every stage — from first contact and screening through verification, storage, and reporting.
HIPAA-aligned safeguards
Health information is handled under U.S. privacy expectations appropriate to the study design and data flows involved.
GDPR-aligned processing
European participants receive processes mapped to GDPR obligations, including lawful bases, transparency, and data-subject rights.
Physician-verified respondents
Clinical confirmation steps reduce noise in small-N samples and protect the integrity of rare disease insights.
Ready to assess feasibility for your study?
We respond within 3–5 business days. Share your objectives and we’ll help you plan verified patient recruitment.